(Q37205954)

18 August 2017

1 reference

title

Pharmacogenetics of analgesics: toward the individualization of prescription (English)

1 reference

18 August 2017

Victoria Rollason

1

1 reference

18 August 2017

Caroline Samer

2

1 reference

18 August 2017

Valerie Piguet

3

1 reference

18 August 2017

Pierre Dayer

4

1 reference

18 August 2017

Jules Desmeules

5

1 reference

18 August 2017

publication date

1 July 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

9

1 reference

18 August 2017

issue

7

1 reference

18 August 2017

page(s)

905-933

1 reference

Pharmacogenetics/genomics and personalized medicine

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The pharmacogenetics of analgesia: toward a genetically-based approach to pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

ABC transporters: physiology, structure and mechanism--an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Genetic polymorphisms of the human MDR1 drug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Implications of genetic polymorphisms in drug transporters for pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

MDR1 genotype-related pharmacokinetics: fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

MDR1 P-glycoprotein transports endogenous opioid peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Genetic variability and clinical efficacy of morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Increased drug delivery to the brain by P-glycoprotein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Lack of interaction of the NMDA receptor antagonists dextromethorphan and dextrorphan with P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Rapid assessment of P-glycoprotein inhibition and induction in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Functional characterization of four allelic variants of human cytochrome P450 1A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Methadone, ciprofloxacin, and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Inhibition of human drug metabolizing cytochrome P450 by buprenorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Clinical consequences of cytochrome P450 2C9 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Allele variants of the cytochrome P450 2C9 genotype in white subjects from The Netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Cytochrome P450 isozymes and antiepileptic drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Impact of environmental and genetic factors on codeine analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Codeine intoxication associated with ultrarapid CYP2D6 metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Impact of CYP2D6 genotype on postoperative tramadol analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Human white blood cells synthesize morphine: CYP2D6 modulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Dextromethorphan and dextrorphan as calcium channel antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize in brain slices

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Clinical implications of drug interactions with coxibs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Significance of the minor cytochrome P450 3A isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Genetic contribution to variable human CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Genetic polymorphism and drug interactions: their importance in the treatment of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Pharmacokinetic interactions with rifampicin : clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Inhibition of alfentanil metabolism by erythromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanyl.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Ritonavir's role in reducing fentanyl clearance and prolonging its half-life.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Possible fluconazole-fentanyl interaction-a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The metabolism of diclofenac--enzymology and toxicology perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the C-glucuronidation of phenylbutazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Drug glucuronidation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

In vitro inhibitory effects of non-steroidal antiinflammatory drugs on UDP-glucuronosyltransferase 1A1-catalysed estradiol 3beta-glucuronidation in human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Heterogeneity of paracetamol metabolism in Gilbert's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Predicting response to lithium in mood disorders: role of genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

COMT Val108/158Met genotype affects the mu-opioid receptor system in the human brain: evidence from ligand-binding, G-protein activation and preproenkephalin mRNA expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

A genetic association study of the mu opioid receptor and severe opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Genetic variability of mu-opioid receptor in an obstetric population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Mu opioid receptor-dependent and independent components in effects of tramadol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The melanocortin-1 receptor: red hair and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Anesthetic requirement is increased in redheads

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Increased sensitivity to thermal pain and reduced subcutaneous lidocaine efficacy in redheads

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Transporters and renal drug elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Pharmacogenomics of the OATP and OAT families

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Sulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Genetic variation in cyclooxygenase 1: effects on response to aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Identification and functional characterization of alpha(2)-adrenoceptor polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The antinociceptive effect of tramadol in the formalin test is mediated by the serotonergic component

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

The analgesic efficacy of partial opioid agonists is increased in mice with targeted inactivation of the alpha2A-adrenoceptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Environmental and genetic factors associated with morphine response in the postoperative period

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

No Influence of ABCB1 Haplotypes on Methadone Dosage Requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Stereoselective Block of hERG Channel by (S)-Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Cytochrome P450 2D6 Genotype and Methadone Steady-State Concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Increased (R)-Methadone Plasma Concentrations by Quetiapine in Cytochrome P450s and ABCB1 Genotyped Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

Genetic Susceptibility to Nonsteroidal Anti-Inflammatory Drug–Related Gastroduodenal Bleeding: Role of Cytochrome P450 2C9 Polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.905

21 January 2018

Identifiers

DOI

10.2217/14622416.9.7.905

1 reference

18 August 2017

1 reference